Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: The first-in-class FGFR3 ADC of Qide Pharma commences clinical trials The U.S. FDA has granted clinical trial approval for GQ1011 (AMB302), a first-in-class ADC targeting fibroblast growth […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Blenrep + BorDex combination accepted for review by US FDA The U.S. FDA has accepted GSK’s Biologics License Application (BLA) for the use of Blenrep (belantamab mafodotin) […]
Weekly Digest – November 2024 Weekly Digest – November 2024 27 Nov 2024: Sacituzumab Tirumotecan Earns Approval in China for Pretreated Advanced TNBC Sacituzumab tirumotecan has been approved by China’s National Medical Products Administration (NMPA) to treat adult patients with […]
Weekly Digest – November 2024 Weekly Digest – November 2024 28 Nov 2024: AstraZeneca’s Enhertu breast cancer drug added to China’s state insurance list AstraZeneca’s breast cancer drug, Enhertu, will be included in China’s state-run health insurance scheme starting January […]
Weekly Digest – November 2024 Weekly Digest – November 2024 18 Nov 2024: VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate VelaVigo Cayman Limited has entered into an agreement with Avenzo Therapeutics, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 19 Nov 2024: LigaChem Biosciences receives near-term milestone payment for ‘LCB97’ from Japan’s Ono Pharmaceutical LigaChem Biosciences received a near-term milestone payment for its LCB97 (L1CAM-ADC) from ONO PHARMACEUTICAL in […]
Weekly Digest – November 2024 Weekly Digest – November 2024 20 Nov 2024: Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time NICE has rejected Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu for the third time, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 20 Nov 2024: FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers The FDA granted fast track designation to ALE.P02, an anti-Claudin-1 (CLDN1) ADC, for the treatment of CLDN1-positive squamous solid […]
Weekly Digest – November 2024 Weekly Digest – November 2024 21 Nov 2024: Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data PYX-201 demonstrated a confirmed 50% objective response rate (ORR) in heavily pretreated HNSCC patients, including […]
Weekly Digest – November 2024 Weekly Digest – November 2024 18 Nov 2024: AbbVie’s ELAHERE Receives EU Approval for Treating Platinum-Resistant Ovarian Cancer AbbVie received European Commission marketing authorization for ELAHERE (Mirvetuximab soravtansine), the first folate receptor alpha-directed ADC approved […]
